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Introduction
Extracellular vesicles (EVs) are membrane-enclosed particles 
released by virtually any cell type into the extracellular milieu 
and detectable in body fluids.1-3 Their abundance has been linked 
to both physiological and pathological conditions, including can-
cer.1,4 EVs are heterogeneous, and a formalized nomenclature is 
still under debate. Most of the current methodologies employed 
to purify microvesicles are based on differential centrifugation 
with or without filtration and are cumbersome and time con-
suming, therefore difficult to apply to the clinical practice. They 
also result in populations of EVs that are contaminated with one 
or more types of EV. This scenario is complicated by the fact 
that the size of most EVs studied to date (~100 nm) is below 
the detection limits of both light and fluorescent microscopy, 
and their visualization requires electron microscopy. This is a 
significant technological barrier that has delayed accurate char-
acterization of different EV populations, thereby inhibiting the 
elucidation of their biological roles and intrinsic clinical value. 
Among the best-characterized EVs, exosomes are 30–100 nm 
particles released to the extracellular space upon fusion of intra-
cellular multivesicular bodies with the plasma membrane.5 Even 
though exosomes are ubiquitous, their molecular content can 
reflect pathological conditions, and quantitative and molecular 
analyses of exosomes in patients with cancer may provide clini-
cally relevant information.6
EVs derived by direct abscission from the plasma membrane 
have also been described.1,7,8 Shedding of these EVs can occur 
following activation of signal transduction pathways and there-
fore may play a role in intercellular communication in cancer and 
other conditions. We recently demonstrated the existence of a 
new class of EVs that can be very large (1–10 µm) and result from 
the shedding of non-apoptotic plasma membrane blebs that char-
acterize fast-migrating “amoeboid” tumor cells. The shedding 
of these “large oncosomes” can be induced in prostate cancer 
(PCa) cells by overexpression of oncoproteins such as MyrAkt1, 
HB-EGF, and caveolin-1 (Cav-1).8 Large oncosome formation 
and shedding was also demonstrated as a result of silencing of the 
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prostate cancer cells release atypically large extracellular vesicles (eVs), termed large oncosomes, which may play a 
role in the tumor microenvironment by transporting bioactive molecules across tissue spaces and through the blood 
stream. In this study, we applied a novel method for selective isolation of large oncosomes applicable to human platelet-
poor plasma, where the presence of caveolin-1-positive large oncosomes identified patients with metastatic disease. this 
procedure was also used to validate results of a miRNA array performed on heterogeneous populations of eVs isolated 
from tumorigenic RWpe-2 prostate cells and from isogenic non-tumorigenic RWpe-1 cells. the results showed that dis-
tinct classes of miRNAs are expressed at higher levels in eVs derived from the tumorigenic cells in comparison to their 
non-tumorigenic counterpart. Large oncosomes enhanced migration of cancer-associated fibroblasts (CAFs), an effect 
that was increased by miR-1227, a miRNA abundant in large oncosomes produced by RWpe-2 cells. our findings suggest 
that large oncosomes in the circulation report metastatic disease in patients with prostate cancer, and that this class of 
eV harbors functional molecules that may play a role in conditioning the tumor microenvironment.
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cytoskeletal regulator Diaphanous-related formin 3 (DIAPH3) 
through an ERK-mediated pathway.9 In a previous study, using 
a differential centrifugation method that does not separate large 
oncosomes from smaller EV, we were able to enrich for large 
oncosomes by immuno-flow cytometry with 1–10 µm specific 
size beads. Using this approach, large oncosomes were identified 
in association with invasive cancer in the circulation of mice, 
and the feature was corroborated in tumor tissue using tissue 
immunostains that detect similar-sized particles.1 Akin to exo-
somes and oncosomes of smaller size, large oncosomes contain 
many classes of signaling proteins relevant to cancer. Given their 
substantially larger volume, large oncosome-enriched fractions 
potentially represent a more expansive reservoir of biomolecules 
than does the exosome EV fraction. Large oncosomes also con-
tain nucleic acids, including miRNA, suggesting that, similarly 
to other EVs, they may mediate horizontal transfer of diverse 
RNA species within and across tissue compartments and to dis-
tant sites through the circulation.10 The relatively recent finding 
that miRNA are present in circulating exosomes11 suggests that 
characterization of the molecular cargo carried by microvesicle-
enclosed miRNA will allow tumor activity and tumor properties 
to be detected and quantified in EV-enriched fractions.
Here we describe a rapid filtration-based approach for direct 
separation of large EVs from smaller microvesicles. Applying this 
new method to cell media, we isolated large EVs in a similar size 
range to large microvesicles purified by medium speed differential 
centrifugation, which has been shown to pellet negligible amounts 
of smaller EVs.1,12 We profiled non-tumorigenic and tumorigenic 
prostate cell lines and derived EVs using an Affymetrix miRNA 
array platform, followed by qRT-PCR validation on large EVs 
selectively isolated using filtration. Our results show that distinct 
classes of miRNAs are differentially expressed in EVs derived 
from tumorigenic in comparison to non-tumorigenic cells, and 
that large oncosome-enclosed miRNA can induce migration of 
cancer-associated fibroblasts (CAFs). Finally, we demonstrated 
that the filtration method is applicable to human platelet-poor 
plasma, in which Caveolin-1-positive large oncosomes identified 
patients with metastatic prostate cancer.
Results
Selective isolation of large EVs
In order to rapidly purify large oncosomes, we applied 
a filtration-based approach to the culture medium of GFP-
overexpressing U87 glioblastoma cells, a cell line with a high 
rate of large oncosome formation compared with other tumor 
cells (Fig. 1A and B). After removing intact cells and cell debris 
from the culture media by low force centrifugation (2800 g), the 
supernatant underwent filtration in columns (nominal diameter 
of the pores = 200 nm) for 30 s at 8000 g on a bench centrifuge. 
Particles larger than 200 nm, retrievable from the top of the filter 
and positive for GFP, were analyzed and sorted by flow cytom-
etry with specific size beads to selectively quantify particles of 
1–10 µm in diameter (Fig. S1A).1 Sorted particles were observed 
by microscopy, which showed large intact vesicular structures in 
the correct size range (Fig. 1C).
To test the efficacy of the filtration approach, we employed 
flow cytometry analysis to compare the size distribution of the 
Figure 1. Comparison between different methods of eVs purification. (A) Large oncosome formation assay in prostate cancer (DU145, pC3), lung cancer 
(pC9), glioblastoma (U87), and bladder cancer (253J) cell lines. (B) Numerous large oncosomes identifiable by microscopy in U87 glioblastoma cells 
stained with CtxB-FItC. (C) GFp-positive large eVs, collected using filtration, were imaged by fluorescence microscopy. (D) Comparative flow cytometry 
analysis of eVs isolated from the medium of U87 cells, by differential centrifugation (10 000 g) or filtration. Both methods allow detection of large eVs in 
a similar size range and modal distribution. (E) NtA of eVs isolated from the medium of U87 cells, by differential centrifugation (10 000 and 100 000 g) or 
filtration. the filtration and the 10 000 g centrifugation results in preparations with negligible amounts of small eVs.
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EVs purified by filtration or by medium speed (10 000 g) dif-
ferential centrifugation. The filtration method was conceived 
with the goal of retaining the target population on the filter and 
letting smaller particles (<200 nm) flow through. Retrieval of 
material on the top of the filter gave rise to a population of large 
EVs (Fig. 1D, right panel) similar in size distribution to the ones 
purified using the centrifugation method (Fig. 1D, left panel). 
As an independent assessment, we quantified smaller EVs (e.g., 
exosomes) by nanoparticle tracking analysis (NTA) (Fig. S1B),13 
a system that allows quantitation of particles smaller than 1 µm. 
The number of small EVs obtained using both filtration and 
centrifugation was minimal when compared with the number of 
small EVs obtained using high-speed centrifugation (100 000 g), 
often used to identify exosomes (Fig. 1E).14,15 Collectively, these 
results indicate that the filtration-based method, similarly to 
10 000 g centrifugation, can be used for the rapid isolation of EV 
preps highly enriched in large oncosomes.
miRNA array analysis of EVs
Using a miRNA array, we sought to analyze the miRNA 
profile in EVs and their cells of origin to investigate whether 
miRNA representation was similar or different between benign 
and tumorigenic epithelial cells and EVs they released. In order 
to reduce cell type-specific variations, we interrogated an iso-
genic system, the non-tumorigenic, immortalized prostate epi-
thelial cells RWPE-1, and the tumorigenic, KRAS-transformed 
RWPE-2 cell line.15 RWPE-2 cells showed a high rate of consti-
tutive plasma membrane budding and large oncosome shedding 
in comparison to RWPE-1 cells, irrespective of the presence of 
EGF or fetal bovine serum (FBS) (Fig. 2A and B), corroborating 
previous results showing that large oncosomes are features of 
malignant cells.1,8
We initially applied an Affymetrix miRNA array to EVs puri-
fied with high-speed centrifugation (100 000 g), which gives rise 
to a mixed population of large and small EVs. Technical repli-
cates showed good signal correlation (Fig. S2). We observed a 
strong correlation between expression levels of the intracellular 
miRNAs of the 2 cell lines (R = 0.944), consistent with their iso-
genic origin, and also a significant correlation between the miR-
NAs detected in the EVs from each of the 2 lines (R = 0.895). 
However, the correlation was lower when we compared intracel-
lular and EV miRNAs in both the non-tumorigenic and tumori-
genic lines (R = 0.706 and 0.649, respectively) (Fig. 2C). Relative 
quantitation of the miRNAs suggested differential representation 
of selected miRNAs in EVs from RWPE-2 (designated EV2) 
and RWPE-1 (designated EV1) in comparison with donor cells 
(Fig. 3) and also identified cell type-specific signal, suggesting 
differential miRNA packaging into EVs from the 2 cell types.
qRT-PCR validation and miRNA profiling of large 
oncosomes
In order to derive information about the contribution of 
large oncosomes to the miRNA profile of the mixed EV popu-
lation, we performed qRT-PCR validation experiments on large 
EVs obtained by filtration (Fig. 1C and D). For this purpose, 
we randomly selected 15 miRNAs that showed at least 1.5-fold 
change in one of the following comparisons: EV1 vs. RWPE-1 
and/or EV2 vs. RWPE-2. The analysis included 4 miRNAs with 
Affymetrix-based fold change below the threshold. Two miR-
NAs with Ct values above 36 were considered non-specific and 
Figure 2. miRNA profiling of prostate cells and derived eVs (Discovery). (A and B) oncosome formation in CtxB-FItC labeled RWpe-1 and RWpe-2 cells, 
was quantitatively analyzed in presence or absence of full medium (FM), serum-free medium (SFM) and eGF. (C) expression levels of 847 miRNAs in cells 
and extracellular vesicle. Scatter plots data show the correlation between: RWpe-2 vs. RWpe-1 cells (R = 0.944), eV2 vs. eV1 (R = 0.895), eV1 vs. RWpe-1 
cells (R = 0.706) and eV2 vs. RWpe-2 cells (R = 0.649). the difference between eV2 vs. RWpe-2 cells and eV1 vs. RWpe-1 cells indicate an active selection 
and secretion of miRNA into eV.
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were excluded from the downstream analysis. Notably, qRT-PCR 
analyses of large EVs (Fig. 3A and B, bottom row) validated all 
miRNAs detected as differentially expressed based upon array 
profiling (top row) of mixed population of EVs. In addition, the 
majority of miRNAs, whose discovery fold-change values were 
right below the threshold, demonstrated consistent trends.
The top 5 differentially expressed miRNAs in EV2 vs. 
RWPE-2 cells, and in EV1 vs. RWPE-1 cells have been described 
as having both oncogenic and tumor suppressor functions 
(Fig. 3C).16-20 Importantly, miR-141 and miR-375, both prostate 
cancer biomarkers,21,22 were identified in EVs from both cell lines, 
with slightly higher levels of miR-375 in EV2 than in the donor 
cell (data not shown). Notably, we identified a subset of miR-
NAs with at least 1.5-fold expression change in EV2 vs. RWPE-2 
cells that did not change significantly in EV1 vs. RWPE-1 cells 
(Fig. S3). Eighteen of these miRNAs were upregulated, while the 
majority (37 out of 55) were expressed 
at lower levels in EV2 in comparison 
with RWPE-2. Interestingly, one of 
the miRNAs functionally relevant 
to prostate cancer, miR-205,23 whose 
pathological loss seems to favor tumor 
progression, was identified as an under-
represented miRNA in EV1 and EV2 
in comparison to the donor cells.
miRNA-target gene network 
analysis
In order to identify pathogenic path-
ways potentially altered by oncosome-
associated miRNAs, we performed a 
network analysis (Ingenuity Pathway 
Analysis [IPA], http://www.ingenuity.
com) of miRNAs with at least 1.5-fold 
expression difference between EV2 
and RWPE-2 donor cells (Fig. S3) and 
with experimentally validated targets 
(n = 17, target filter [IPA]) (Fig. 4A). 
The network analysis revealed that the 
top 10 biological functions affected by 
several of the EV2-enclosed miRNAs 
include cell proliferation, cell cycle 
progression, and epithelial neoplasia 
(Fig. 4B), all commonly altered in can-
cer. Interestingly, most miRNAs with 
known oncogenic targets were present 
at low levels in EV2, suggesting that 
EV from malignant cells are relatively 
depleted in miRNAs that inhibit the 
expression of oncogenic proteins.
Targets of most of the miRNAs that 
were expressed at lower levels in EV2 
than in the donor cells include key reg-
ulators of cell proliferation, such as the 
cyclin-dependent kinase CDK6 and the 
transcription factor E2F1. This group 
of miRNAs includes miR-182, let-7i, 
miR-103, miR-107, miR-23a, miR-
23b, miR-92a, and miR-149, all with a 
known role in cancer. Notably, 15 miR-
NAs, including miR-23b, miR-708, 
miR130a and miR-149, are involved 
in tumor cell proliferation, and all of 
the analyzed miRNAs are involved in 
epithelial neoplasia. Interestingly, we 
Figure  3. qRt-pCR validation of the discovery experiment using the filtration method, and relative 
quantitation of miRNAs detected in both eV and donor cells. taqMan qRt-pCR levels of miRNAs in eV2 
vs. RWpe-2 cells (A), and eV1 vs. RWpe-1 cells (B). (C) Relative quantitation of the miRNAs with at least 
1.5-fold expression change (red dotted lines) in eV2 vs. RWpe-2 cells (left panel), and in eV1 vs. RWpe-1 
cells (right panel). Red and green boxes show the top 5 or bottom 5 expressed miRNAs, respectively.
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found that most EV2-associated miRNAs are also implicated 
in the regulation of proliferation and differentiation of stroma 
(Fig. 4B). Because these 2 biological functions have been linked 
to reactive stroma, a hallmark of aggressive cancer,24 these data 
suggest that EV-enclosed miRNAs can potentially affect prostate 
cancer progression by favoring the establishment of a permissive 
tumor microenvironment. In line with this hypothesis, and rel-
evant to large oncosome function, we show that large EVs isolated 
both by differential centrifugation and by filtration, induce pro-
liferation of CAFs (Fig. 4C).
Large oncosomes induce migration of cancer-associated 
fibroblasts (CAFs), and the effect is enhanced by miR-1227
Among the miRNAs that exhibited at least 1.5-fold higher 
levels in EV2 than in EV1 (Fig. 5A), we focused our attention on 
miR-1227, whose overexpression in EV2 vs. RWPE-2 donor cells 
was validated by qRT-PCR (Fig. 3A), and for which functional 
characterization in cancer cells is lacking. Transient overexpres-
sion of a miR-1227 mimic construct in RWPE-2 cells (Fig. 5B) 
resulted in a significant increase of the miRNA levels in the large 
oncosome fraction (Fig. 5C). miR-1227 overexpression in large 
Figure 4. Large oncosomes induce migration of cancer-associated fibroblasts (CAFs), and the effect is enhanced by miR-1227. (A) List of miRNAs differ-
entially expressed in eV2 compared with eV1. (B) RWpe-2 cells were transfected with miR-1227 mimic, or control vector (miR-NC) and the relative amount 
of miR-1227 was determined using qRt-pCR at the indicated times. (C) qRt-pCR analysis using miR-1227 specific primers was performed on total miRNA 
isolated from large and small eVs (10 000 and 100 000 g) from RWpe-2 overexpressing miR-1227 mimic. (D) Crystal violet assay of CAFs treated for 48 h 
with large eVs overexpressing miR-1227 mimic or miR-NC showing that overexpression of the miRNA does not affect cell proliferation. (E) Migration of 
CAFs was enhanced by large eVs overexpressing miR-1227.
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oncosomes did not influence proliferation of CAFs in compar-
ison to controls, but did induce a significant increase in their 
migration (Fig. 5D and E).
Immuno-capture of large oncosomes using cancer 
biomarkers
Next we attempted to employ the filtration-based method 
to isolate green fluorescent protein (GFP)-labeled large onco-
somes from the conditioned media of U87 and LNCaP cells 
stably expressing GFP. Flow cytometry identified abundant GFP-
positive EV of 1–10 µm in the media of U87/GFP (Fig. 6A), 
consistent with the observed high production of large oncosomes 
in that cell type (Fig. 1A and B), whereas they were almost unde-
tectable in the media of LNCaP/GFP cells (64.7% and 1.8%, 
respectively) (Fig. S4A), consistent with our previous demon-
stration of a low rate of large oncosome formation in LNCaP 
cells.8 The distribution of the events in relationship to the size 
is shown in Figure 6B, and we confirmed the presence of intact 
large oncosomes by microscopy (data not shown). Overall, the 
results indicate that the filtration-based method allows rapid and 
efficient isolation of large oncosomes from the conditioned media 
of cancer cells.
We attempted to employ filtration to isolate and quantify 
large oncosomes from conditioned media of DU145 prostate 
cancer cells using Cav-1 and ARF6 antibodies against endog-
enous targets.8,12 Cav-1 is a validated prostate cancer biomarker 
found in the circulation of patients with advanced disease,25 and 
ARF6 is a GTPase shown to be enriched in large EV and to pro-
mote their abscission from cancer cells.12 Using immuno-flow 
cytometry with Cav-1 and ARF6 antibodies against preparations 
obtained from DU145 cell media in combination with the fil-
tration protocol, we detected large EVs positive for both Cav-1 
and ARF6 (Fig. 6C). Because ARF6 may be a specific marker of 
large microvesicles, these data suggest that ARF6 and Cav-1 are 
viable targets for detection and isolation of large oncosomes using 
immunoaffinity capture in concert with the filtration protocol.
Large oncosomes containing Caveolin-1 can report meta-
static disease in patients with prostate cancer
We previously demonstrated that Cav-1-positive large onco-
somes, purified using conventional centrifugation-based protocol 
and analyzed by flow cytometry using sizing beads, were present 
in the circulation of mice with metastatic prostate cancer.1 Since 
the filtration method allowed the rapid isolation of large onco-
somes from the cultured media of cancer cell lines, and Cav-1 
is a validated prostate cancer biomarker, we next attempted to 
use this approach to identify large oncosomes in platelet-poor 
plasma of patients with prostate cancer. Flow cytometry of large 
EVs purified from 200 µl plasma of 6 patients with low Gleason 
grade primary tumors and 6 patients with castration-resistant 
prostate cancer (CRPC) demonstrated a correlation between the 
number of 1–10 µm Cav-1-positive events and metastatic disease 
(P value = 0.0060) (Fig. 7), indicating that large oncosome abun-
dance reflects disease status in patients. These results indicate 
that the filtration protocol we have described 
can provide a valid alternative to differential 
centrifugation methods to isolate and quan-
tify tumor-derived large oncosomes from 
human blood.
Discussion
This is the first study describing a rapid 
method, based on filtration, for selective 
purification of large oncosomes. Using the 
new method, we demonstrated for the first 
time that: (1) the number of circulating Cav-
1-positive large oncosomes is increased in 
metastatic in comparison with organ-con-
fined disease in patients with prostate can-
cer; (2) the method is suitable for molecular 
profiling of large oncosomes; (3) miRNA 
analyses indicate that distinct classes of 
miRNAs are differentially expressed in EVs 
derived from tumorigenic than from non-
tumorigenic cells; (4) miR-1227, which can 
be preferentially loaded into large oncosomes 
vs. smaller EV, is a novel modulator of the 
migration of CAFs.
With the growing realization that EVs 
play important roles in tumor dissemina-
tion and also represent an important source 
of novel biomarkers,2,6,26 there is an urgent 
need to develop standardized, clinically 
Figure  5. miRNA-target gene network analysis. (A) Green and red symbols denote low- and 
high-expressed miRNAs, respectively. Gray lines indicate inhibitory effect of miRNAs on target 
genes. (B) target genes of miRNAs expressed at significantly lower or higher levels in eV2 than 
in RWpe-2 cells, but at non-significantly lower or higher levels in eV1 vs. RWpe-1 cells, were con-
sidered for the Ingenuity pathway Analysis (IpA). Bars indicate the top 10 biological functions 
in decreasing order of significance. (C) Cell proliferation of CAF treated for 48 h with large eVs 
isolated from RWpe-2 using differential centrifugation (10 000 g) or filtration.
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applicable methods for the isolation and characterization 
of homogeneous EV subtypes against a background of 
heterogeneous EV populations. Most methods used cur-
rently were developed to characterize nanosized exosomes, 
and filtration steps purposely exclude larger microvesicles 
from the preps. Conversely, our filtration-based approach 
allows selective purification of large oncosomes and should 
facilitate more extensive characterization of this class of EV. 
The large oncosome is potentially a significant reporter 
of cancer activity in the body, given its large volume and 
content of tumor-derived molecules1,27-29 (and unpublished 
observations). One potential caveat of the filtration method 
is low efficiency, as the total number of particles isolated by 
filtration is lower in comparison with a medium force speed 
(10 000 g) used to selectively purify large EVs. However, 
the observation that we can quantitatively discriminate 
between metastatic and primary tumor, and the fact that 
we can analyze the molecular content of large oncosomes, 
argue in favor of the utility of this method in clinical 
translation.
The demonstration that the new method is also suitable 
for analysis of the miRNA cargo of large oncosomes, and 
that >60% of the miRNAs are expressed at similar levels 
between donor cells and derived EVs, suggests that some 
miRNAs are shuttled into the particles because of subcel-
lular location or mass action, indicating that the miRNA 
content of the particle is representative of the donor cell. 
Therefore, EVs are a potential source of circulating mark-
ers of solid tumor bioactivity or response to therapy. 
Importantly, prostate cancer miRNA biomarkers miR-141 
and miR-375 were identified in EVs. In addition, one of the 
miRNAs expressed at higher levels in EVs from the tumori-
genic cell line, miR-1228, was recently incorporated into a 
tissue miRNA signature of clinical progression in patients 
with endometrial carcinoma.30 Other miRNAs expressed at 
high levels in EVs from the tumorigenic RWPE-2 subline 
have not been functionally studied. Interestingly, pathway 
analysis demonstrated that the top 10 biological functions 
affected by the 2 miRNAs enriched in EV from the tumori-
genic cells are commonly altered in cancer.
Besides the miRNAs expressed at similar levels, our data 
also show that several miRNAs are differentially expressed 
in donor cells and EVs, suggesting that the packaging of 
Figure  6. the filtration method allows selective purification of large onco-
somes. (A) GFp-positive large eVs were purified from the conditioned media 
of U87/GFp cells by filtration and analyzed by flow cytometry. (B) eV size dis-
tribution (left) and quantitative analysis (right) as measured by flow cytometry 
analysis in 3 independent experiments. (C) Large eVs, purified from the con-
ditioned media of DU145 cells by filtration, were quantitatively analyzed by 
immuno-flow cytometry with Cav-1 (left) and ARF6 (right) antibodies.
Figure 7. Large oncosomes isolation. (A) Workflow showing the filtration-based method for the isolation of large oncosomes. After a low g force cen-
trifugation step to remove intact cells and cell debris, the filtration-based method was employed to purify eVs from human plasma. (B) the number of 
Cav-1-positive large eV in 200 µl of platelet-poor plasma was significantly more abundant in the plasma of patients with metastatic disease (P value = 
0.0060) than with organ-confined prostate cancer (LG, low-grade Gleason score).
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miRNAs into EVs does occur in part by active selection. These 
data appear consistent with recent findings showing the presence 
in EVs of transcripts of the membrane vesiculation machinery, as 
well as nucleic acids encoding essential enzymes for miRNA syn-
thesis.27 These findings are supportive of the recently proposed 
hypothesis that miRNA biogenesis occurs within EVs.31
While differences in miRNA levels in EVs and donor cells 
have been reported for other types of cell lines,32-34 this is the first 
side-by-side comparison of the miRNA profile of EVs derived 
from tumorigenic and non-tumorigenic cells. The finding that 
the top 5 differentially expressed miRNAs in EVs from the 
tumorigenic subline are distinct from those in the non-tumor-
igenic subline suggests the possibility that these molecules may 
alter the tumor microenvironment or distant sites when derived 
from cancer cells. In line with this hypothesis, our functional 
studies demonstrated that miR-1227, one of the top 5 differen-
tially expressed miRNAs in EVs from the tumorigenic subline 
RWPE-2, could elicit biological effects in CAFs (increased cell 
migration). This result suggests that miR-1227 plays a role in the 
promotion of migration induced by the large oncosomes, as is the 
case for other miRNAs carried in different types of EVs.35 The 
fact that miR-1227 does not seem to be involved in regulating 
proliferation of CAFs, while large oncosomes can promote cell 
proliferation, suggests that large oncosome-mediated effects on 
proliferation might be dependent on different oncosome cargo. 
Of interest, the overexpression of a miR-1227 mimic in RWPE-2 
cells resulted in a more dramatic increase of the miRNA levels in 
large oncosomes than in smaller EVs, suggesting an overall larger 
potential for large oncosomes than for smaller EVs to transfer 
bioactive molecules between cell compartments.
The finding that a considerable number of miRNAs described 
as tumor suppressors in several types of tumors, including pros-
tate cancer,22,36-45 were underrepresented in EVs from the tumori-
genic RWPE-2 cell line might be a simple reflection of overall 
low miRNA expression in prostate cancer in comparison with 
normal tissue, and of progressively lower miRNA expression 
with progression to advanced disease.46 It is interesting that miR-
205, which has a known tumor-suppressor function and is lost 
in advanced disease,46-48 was not loaded at high levels in EV1 and 
EV2 in comparison to other miRNAs. This suggests the possibil-
ity that tumor suppressor miRNAs may be present at relatively 
low levels in EV from malignant cells.
Our results suggest that Cav-1-positive large oncosomes 
can report metastatic disease in patients with prostate cancer, 
as demonstrated quantitatively by immuno-flow cytometry of 
the purified vesicles. We recently showed that the number of 
plasma-derived Cav-1 large oncosomes correlates with disease 
progression in a mouse model of prostate cancer.1 In the same 
study, we showed that large oncosomes identified in prostate 
cancer tissues in situ could discriminate aggressive disease.1 
However, the findings reported here are the first demonstration 
of the potential clinical significance of circulating Cav-1-positive 
large oncosomes in patients with cancer. Because this analysis 
was performed on 200 μl of plasma, a much smaller amount 
than what has been reported in virtually all other studies on EV 
purification from biological fluids, the result suggests that this 
or a similar approach may have clinical utility. Given their size 
and the possibility of identifying large oncosomes in tissues by 
microscopy,1 the molecular characterization of these EVs might 
be validated by in situ detection of altered transcripts and other 
molecules initially identified in the circulation of patients with 
cancer.
In conclusion, large oncosome characterization can provide 
clinically valuable information in patients with cancer, and a 
focus on this large class of EVs may benefit functional and molec-
ular studies.
Materials and Methods
Cell culture
RWPE-1, RWPE-2, LNCaP, and DU145 cells were from the 
American Type Culture Collection (ATCC). U87 cells were a 
gift from Dr Michael Klagsbrun, Boston Children’s Hospital. 
The base medium for RWPE-1 and RWPE-2 cell lines was 
Keratinocyte Serum-Free Medium (K-SFM), supplemented with 
0.05 mg/ml bovine pituitary extract (BPE) and 5 ng/ml epider-
mal growth factor (EGF), 100 U/ml penicillin, and 100 µg/ml 
streptomycin. For the generation of LNCaP/GFP and U87/GFP 
cells, parental LNCaP and U87 cells were plated at 70–80% 
confluence and transfected using Lipofectamine™ 2000 (Life 
Technologies) with the plasmid pEGFP-C3. Stable populations 
were isolated following selection with Geneticin G418 0.5 mg/
ml (LNCaP/GFP) and 0.4 mg/ml (U87/GFP). LNCaP, DU145, 
and U87 cells were cultured in RPMI-1640, DMEM and 
MEM medium, respectively. All media were supplemented with 
10% fetal bovine serum (FBS; Valley Biomedical) 2 mmol/L 
L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
CAF were cultured in DMEM/F12 supplemented with 5% fetal 
bovine serum and 5% Nu-serum, 10−9 M testosterone 2 mmol/L 
L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
Unless otherwise specified, media and supplements were from 
Invitrogen.
Immunofluorescence microscopy and large oncosome-for-
mation assay
Cell membranes were labeled with FITC-conjugated chol-
era toxin subunit B (CTxB; Sigma) and analyzed as previously 
described.8
Purification of EV by differential centrifugation
Shed EVs were collected from conditioned media and purified 
as described.8 Briefly, 1.6 × 107 cells per plate from 18 150 mm2 
plates, were cultured in serum-free media for 24 h. Culture super-
natants was collected and centrifuged at 2800 g for 10 min (4 °C) 
to eliminate cells and cell debris. Supernatants were sequentially 
centrifuged (Beckman SW28 rotor) by low g force centrifugation 
at 10 000 g (30 min, 4 °C), followed by high g force centrifu-
gation at 100 000 g (1 h, 4 °C). After each centrifugation step, 
EVs were collected from the bottom of the centrifuge tubes using 
double-filtered (0.22 µm) ice-cold PBS and stored at −80°C.
Patient specimens
Plasma samples used in this study were obtained through 
an institutional review board approved protocol in compliance 
with the Declaration of Helsinki. All subjects provided written 
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informed consent for blood to be used for research purposes. 
Patient samples were obtained from the Urologic Oncology 
Program and the Cedars-Sinai BioBank.
EV isolation by filtration
For the isolation of EVs from cultured cells, culture superna-
tants from 3 150 mm2 plates or 200 µl of platelet-poor plasma 
were collected and centrifuged at 2800 g for 10 min to eliminate 
cells and cell debris. Supernatants were then filtered at 8000 g for 
30 s at 4 °C using Vivaspin 500 Ultrafiltration Spin Columns 
(Sartorius Stedim) with 0.2 µm polyethersulfone (PES) mem-
brane. Large oncosomes, deposited on top of the filter in a vol-
ume of 20 µl, and smaller EVs, collected in the filtrate, were 
recovered and stored at −80 °C.
Immuno-flow cytometry
EVs purified by filtration were fixed in 4% formaldehyde and 
stained with Cav-1 or ARF6 antibodies (1:200), followed by a 
FITC- or Cy3-conjugated antibody. EVs were processed on an 
Aria III Cell Sorter (Becton Dickinson). Background signal was 
set up on double 0.22 µm filtered PBS, allowing an event rate of 
0–4 events/sec using high sheath pressure, whereas sample analy-
ses were performed using low sheath pressure, thus maximizing 
the amount of scattered light and fluorescence coming from EVs. 
Light scattering detection was performed in log and linear mode. 
Bead standards of 1, 2, 4, 6, and 10 µm (Invitrogen) were used 
to set size gates. At least 3000 events were recorded, and data 
were analyzed using FlowJo software (Treestar). Comparisons 
between experimental groups were performed using 2-tailed, 
unpaired Student t test.
Nanoparticle tracking analysis (NTA)
Approximately 300 µl EV suspensions were loaded into the 
sample chamber of a NanoSight LM20 (NanoSight) using sterile 
syringes. Videos of 40 or 60 s were recorded for each sample, 
and particle movement was analyzed by NTA software (version 
2.3 Build 0006 BETA2). A minimum of 200 completed particle 
tracks were analyzed in each video. NTA software settings were: 
frames per second, 37.80; calibration, 172 nm/pixel; detection 
threshold, 6–8 Muti; blur, auto; min track length, auto; tem-
perature, 22–25 °C; viscosity, 0.89 cP. Manual shutter and gain 
adjustments were used during the experiment.49
miRNA profiling
Total RNA was extracted from RWPE-1 and RWPE-2 cells 
as well as from mixed populations of EVs (referred to as EV1 
and EV2) purified using the 100 000 g centrifugation, by TRIzol 
(Invitrogen), and profiled using Affymetrix GeneChip® miRNA 
Arrays (Affymetrix) containing 847 human mature miRNAs 
(Asuragen Services). Following incoming sample quality con-
trol (QC) assessment, the 3′ ends of RNA molecules in total 
RNA samples were labeled with biotin according to the com-
pany’s standard protocol and purified and profiled in duplicate. 
Hybridization, washing, staining, imaging, and signal extrac-
tion were performed according to Affymetrix-recommended 
procedures. Arrays were scanned on an Affymetrix GeneChip® 
Scanner 3000 7G. Raw data were normalized by computing 
the global Variance Stabilization Normalization (VSN)50 of 
all the arrays. Each technical duplicate resulted in good signal 
correlation (Fig. S1). Downstream analysis was performed by 
aggregating single experiment data on a sample basis using the 
mean. Data were then scaled to assume values above or equal 
to one. miRNA fold changes and differences were calculated for 
EV1 over RWPE-1, EV2 over RWPE-2, EV2 over EV1, RWPE-2 
over RWPE-1. Fold-change <1 were transformed as y(x) = (−1/×). 
Due to sample size, no statistical test was applied to assess differ-
ential miRNA expression, and data were portrayed as fold change 
values with a cutoff of 1.5.
Quantitative PCR
For quantitative PCR, total RNA was prepared with the mir-
Vana miRNA isolation kit (Ambion) according to the manu-
facturer’s protocol. Total RNA (15 to 35 ng) was subjected to 
reverse transcription using the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems) with 3 µl of miRNA 
assay RT primers in a final reaction volume of 15 µl. cDNA was 
diluted and set up in triplicate qRT-PCRs containing 1 µl of 
specific TaqMan miRNA assay and run on a ABI 7500 Fast Real-
Time PCR System (Applied Biosystem). Data were analyzed by 
the ΔΔC
t
 method. Relative expression levels of each miRNA were 
normalized using EV1, EV2, RWPE-1, and RWPE-2 as reference 
and RNU6B as endogenous control.51
Overexpression of miR-1227
We employed miR-1227 mimic (cat. no. 4464066, spe-
cific identifier MC13370), which mimics mature endogenous 
miRNA, to overexpress miR-1227 in RWPE-2 cells. miRNA 
mimic negative control (cat. no. 4464058), miR-NC, was used 
as negative control. Cells were transfected using Lipofectamine™ 
LTX for the indicated times. The levels of miR-1227 mimic 
were determined using qRT-PCR and normalized to endog-
enous control RNU48 expression. All reagents were from Life 
Technologies.
Proliferation assay and migration assay
Cell proliferation and cell migration of CAF was performed 
using large EVs from RWPE-2 cells infected with miR-1227 or 
miR-NC. Both assays were performed as previously described.52
miRNA-target gene network and pathway analysis
miRNA targets for miRNAs expressed at significantly 
differential levels in EV2 than in RWPE-2 cells, but at non-
significantly differential levels in EV1 vs. RWPE-1 cells, 
were identified using Ingenuity Pathway Analysis Software 
(Ingenuity Systems). miRNA Target Filter was then applied to 
identify experimentally validated targets in cancer. Selected tar-
gets were used to build the miRNA-target gene network and 
were subjected to systematic network analysis to determine 
the top biological functions. Right-tailed Fisher exact test (P < 
0.05) was used to calculate P value determining the probability 
that each biological function assigned to that data set is due to 
chance alone.
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